Descrizione del progetto
Ridurre i costi del trattamento di disturbi cerebrali attraverso l’intelligenza artificiale
Nel settore sanitario, i costi del trattamento dei disturbi cerebrali rappresentano una percentuale significativa dei costi totali di trattamento. In Europa, il bilancio per il trattamento dei disturbi cerebrali supera di gran lunga i bilanci combinati di altre malattie. Ricorrendo a un’intelligenza artificiale (IA) all’avanguardia, il progetto ALAMEDA, finanziato dall’UE, potrebbe ridurre notevolmente i costi del trattamento di queste condizioni, consentendo una cura personalizzata e trattamenti migliori per i principali disturbi cerebrali. L’obiettivo consiste nel dimostrare una previsione, una prevenzione e un intervento abilitati all’IA, rendendo più economico il trattamento di disturbi quali il morbo di Parkinson, la sclerosi multipla e l’ictus e alleggerendo l’onere dei sistemi sanitari europei.
Obiettivo
Direct costs of brain disorders make up for 60% of the total costs – which EBC estimated at 800 bln€/year in Europe. At European level, this health budget far exceeds that of cardiovascular diseases, brain diseases and diabetes together. ALAMEDA will research, develop and exploit the next generation of personalized AI healthcare support systems that improve the rehabilitation treatment of Parkinson’s, Multiple Sclerosis, and Stroke (PMSS) patients. Stemming from very specific clinical use cases, ALAMEDA will develop user-friendly solutions that will be designed and evaluated on the principles of value-based health. The consortium brings together established medical research teams, AI researchers, medical software vendors and healthcare market experts to demonstrate AI-based personalised prediction, prevention, and intervention approach in three (3) real world pilots. Liaisons have been established with projects MULTI-ACT and IDEA-FAST and the carefully structured workplan, embodies an integrated and harmonized approach with active patients’ engagement towards meeting the ALAMEDA objectives and delivering market-relevant outcomes of significant exploitation potential.
Campo scientifico
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesbasic medicineneurologystroke
- medical and health sciencesbasic medicineneurologyparkinson
Parole chiave
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-DTH-2020-1
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
106 82 ATHINA
Grecia